Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinhua Miyanling is a Traditional Chinese Medicine (TCM) formulation developed by Jilin Huakang Pharmaceutical. It is primarily available as a tablet and is composed of extracts from ten medicinal herbs, including *Lonicera japonica* (honeysuckle), *Lobelia chinensis*, and *Polygonum aviculare*. The drug is indicated for the treatment of urinary tract infections such as cystitis, urethritis, and pyelonephritis, particularly those associated with the TCM syndrome of 'damp-heat downward infusion.' It has also been investigated in Phase 3 clinical trials for the treatment of type III prostatitis (chronic prostatitis/chronic pelvic pain syndrome). The therapeutic action of Yinhua Miyanling is attributed to its combined antibacterial, anti-inflammatory, and diuretic properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinhua Miyanling.